Glargine U300 - A Novel Approach in Managing Type 2 Diabetes
Dr. Jamal Ahmad discusses type 2 diabetes as a chronic, progressive disorder affecting. Comorbid conditions associated with diabetes include cardiovascular disease, heart failure, chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH), and foot problems.Various regimens, such as basal insulin, premixed insulin, and multiple daily injections, are used to treat type 2 diabetes. Both international and national bodies recommend basal insulin.
Dr. Ahmad's experience and literature findings indicate that Insulin Glargine 300 (Gla-300) is superior to Insulin Glargine 100 (Gla-100) in reducing A1C, overall hypoglycaemia, and nocturnal hypoglycaemia. Gla-300 has a peak less profile, lasts more than 36 hours, and offers a simple regimen for initiating and intensifying basal insulin. Continuous glucose monitoring (CGM) has shown improved glycaemic variability with Gla-300 is suggested as the preferred choice for type 2 diabetes patients not achieving control with these agents and highlights its safety in type 1 diabetes and associated comorbidities.
Hello, good afternoon to all my colleagues, doctors and others. I am Dr. Jamal Ahmad, practicing undercologist for more than 35 years. At present I am in a Uighur and previously I have been in post-sarapantarupanandit, Pagati, Amalizan, in the general college as a living industry. I am sure you all know that type 2 diabetes is a chronic positive degenerative disorder. At the moment we have got 101.3 million people who are suffering from this disease. You are all aware of the comal root conditions associated with diabetes, be a cardiovascular disease, heart failure, seek safety, NASH, food problems and other related comal root conditions. Despite the availability of so many anti-happaglacic agents, not more than 35 or 36 percent people are able to achieve lysine control. The latest in the Uighur and the same, the same percent. There are so many regimens which are used for the treatment of type 2 diabetes as for the disease. The disease is concerned via a basal insulin, the premixed insulin or multidotensuline injections. All the international as well as national body recommend that it that basal insulin is the choice of therapy in people who type 2 diabetes who are not able to achieve lysine control, despite using three anti-happaglacic agents. My experience as well as experience from the literature for the use of lysine 300 in people with type 2 diabetes. The glysine 300 what I found and whatever the literature speaks, there is also always a fear of hypoglycemia and weight gain in people who are using other form of therapy. What we have found that use of lysine 300 is superior to double duct to glysine 100 in terms of achieving A1C reduction in terms of reducing any type of lysine in terms of reducing nocturnal lysine. It has a lot of peakless profile, duration of action is more than 36 hours and a very simple regimen to have initiation and intensification of basal insulin that is glysine 300. In the CGM monitoring also we have seen that the glysine 300 use has improved the correction of lysine variability. I just want to give you clear message to all my fellow colleagues, glysine 300 should be a preferred choice if a person with type 2 diabetes is not able to achieve lysine with control despite using 3 anti-happleglysine agent in the sub-maxment dose. It is also safer to be used also in the type 1 diabetes and the comalbit condition that I have mentioned. Thank you so much.
00:00:26 to 00:00:50
1. Anjana RM, Ranjit Unnikrishnan, Mohan Deepa, Rajendra Pradeepa, Tandon N, Ashok Kumar Das, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). THE LANCET Diabetes & Endocrinology. 2023 Jun 1;
2. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of Diabetes and Diabetes-Related Complications. Physical Therapy [Internet], 2018 Nov 1;88(11):1254-64. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870323/
00:00:51 to 00:01:41
3. Bin Rakhis SA, AIDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic Control for Type 2 Diabetes Mellitus Patients: A Systematic Review. Cureus.2022 Jun 21:14(6).
4. Barnett A, Begg A. Dyson P, Feher M. Hamilton S, Munro N. Insulin for type 2 diabetes: choosing a second-line insulin regimen. International Journal of Clinical Practice. 2008 Oct 15;62(11):1647-63.
00:01:42 to 00:02:38
5. Joshi SR, Singh G, Marwah A, Mittra S, Suvarna VR, Athalye SN. Comparative clinical efficacy and safety of insulin glargine 300 U/ml versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis. Diabetes, Obesity and Metabolism. 2023 Feb 28:
6. Blair HA, Keating GM. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus. Drugs. 2016 Jan 28;78(3):383-74.
00:02:39 to 00:03:17
5. Joshi SR, Singh G, Marwah A, Mittra S, Suvarna VR, Athalye SN. Comparative clinical efficacy and safety of insulin glargine 300 U/ml versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis. Diabetes, Obesity and Metabolism. 2023 Feb 28:
